SMT C11003 - A Phase 1b placebo-controlled, multi-centre, randomized, double-blind 3-period dose escalation study to evaluate the pharmacokinetics (PK) and safety of SMT C1100 in paediatric patients with Duchenne Muscular Dystrophy (DMD) who follow a balanced diet.
A Phase II, Randomized, Open-Label, Active-Controlled Clinical Study to Investigate the Safety and Efficacy of SMT19969 (200 mg BID) for 10 days Compared with Fidaxomicin (200 mg BID) for 10 days for the Treatment of Clostridium difficile Infection (CDI) - CoDIFy
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED STUDYTO COMPARE THE EFFICACY AND SAFETY OF RIDINILAZOLE (200 MG,BID) FOR 10 DAYS WITH VANCOMYCIN (125 MG, QID) FOR 10 DAYS INTHE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION (CDI).
100 Clinical Results associated with Summit (Oxford) Ltd.
0 Patents (Medical) associated with Summit (Oxford) Ltd.
100 Deals associated with Summit (Oxford) Ltd.
100 Translational Medicine associated with Summit (Oxford) Ltd.